Sotera Health Company (SHC)

Sotera Health Co. stock has experienced several notable events and movements in the past six months. Sessa Capital disclosed a major buy of Sotera Health in February 2026. The company reported its Q4 CY2025 earnings on February 24, 2026, exceeding revenue expectations. Sotera Health announced a secondary offering of common stock on March 4, 2026. The company completed a follow-on equity offering of $381.75 million on March 15, 2026. Kenneth D. Krause was appointed to its Board of Directors on March 16, 2026. Shares surged 6.95% in mid-day trading on March 31, 2026, and short interest in SHC increased by 19.4% in March.

The demand for Sotera Health's products and services is generally stable due to the mission-critical nature of its offerings. The company's business model benefits from strong customer loyalty and recurring revenue streams. In early 2026, Sotera Health expanded capacity at several sterilization facilities to meet rising demand. The Nordion segment ensures a stable supply chain for gamma sterilization.

Sotera Health Company is a global provider of sterilization solutions, lab testing, and advisory services for the healthcare industry. The company operates through three main businesses: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services. Nordion supplies Cobalt-60 and gamma irradiators. Nelson Labs offers outsourced microbiological and analytical chemistry testing and advisory services.

Sotera Health has a broad global presence with geographical segments including the United States, Canada, Europe, and other regions. The company generates its maximum revenue from the United States. Sotera Health serves over 5,800 customers worldwide and operates a global network of 63 facilities in 13 countries.

Sotera Health positions itself with the mission "Safeguarding Global Health®". The company plays a vital role in the global healthcare infrastructure. However, Sotera Health has faced challenges related to its use of ethylene oxide (EO) in sterilization processes, including a significant settlement in 2023. In early 2026, Sotera Health implemented advanced emission control systems across its U.S. facilities.

Sotera Health's ownership is predominantly held by institutional investors. Major institutional owners include Warburg Pincus LLC, Darsana Capital Partners LP, and GTCR LLC. Michael B. Petras Jr., the Chairman and CEO, holds 1.7% of the shares. The general public holds about 19% ownership.